JMJD2A Antibody [B12L5]

Catalog No.: F0785

    Home Primary Antibodies JMJD2A Antibody [B12L5]

    For research use only.

    Application: Reactivity:

    Usage Information

    Dilution
    1:1000
    1:100
    1:100
    1:200
    Application
    WB, IP, IHC, IF
    Reactivity
    Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    150 kDa

    Datasheet & SDS

    Biological Description

    Specificity
    JMJD2A Antibody [B12L5] detects endogenous levels of total JMJD2A protein.
    Clone
    B12L5
    Synonym(s)
    Lysine-specific demethylase 4A; JmjC domain-containing histone demethylation protein 3A; Jumonji domain-containing protein 2A; [histone H3]-trimethyl-L-lysine(36) demethylase 4A; [histone H3]-trimethyl-L-lysine(9) demethylase 4A; KDM4A; JHDM3A; JMJD2; JMJD2A; KIAA0677
    Background
    JMJD2A, a member of the Jumonji C (JmjC) domain-containing histone demethylase family, is a pivotal epigenetic regulator that modulates gene expression through chromatin remodeling. JMJD2A contains several conserved domains, including two leukemia-associated protein/plant homeodomain (LAP/PHD) zinc fingers, one JmjN domain, a JmjC catalytic domain, and two Tudor domains; the Tudor domains specifically recognize methylated histones such as H3K4, H3K9, and H4K20, facilitating chromatin targeting. The JmjC domain mediates demethylase activity via an iron- and α-ketoglutarate-dependent oxidative mechanism that removes tri- and dimethyl groups from lysine residues on histone H3, predominantly targeting H3K9 and H3K36. The catalytic core structure shows a highly specific substrate recognition involving the main chain interactions and a proline-induced bent conformation of the histone peptide for optimal fit into the active pocket, dictating enzymatic specificity. JMJD2A plays dual roles in transcriptional activation and repression by interacting with retinoblastoma protein (pRb) and histone deacetylases (HDACs), thereby modulating E2F-regulated promoters and influencing cell proliferation and oncogenesis. Overexpression and dysregulation of JMJD2A are linked to multiple cancers.
    References
    • https://pubmed.ncbi.nlm.nih.gov/15927959/
    • https://pubmed.ncbi.nlm.nih.gov/17567753/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.